NCT06533579

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

RecruitingPHASE1, PHASE2INTERVENTIONAL

Trial Details

Start: 2025-05-30Est. Completion: 2027-06

Enrollment target: 32 participants

Locations

City of Hope, Duarte, California, United States
Valkyrie Clinical Trials, Los Angeles, California, United States
Colorado Blood Cancer Institute, Denver, Colorado, United States
Mayo Clinic, Clinical Trials Referral Office, Jacksonville, Florida, United States
Mayo Clinic, Clinical Trials Referral Office, Rochester, Minnesota, United States
New York Medical College, Valhalla, New York, United States
University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill, North Carolina, United States
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
Oregon Health & Science University, Portland, Oregon, United States
TriStar BMT, Nashville, Tennessee, United States
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Contact

Other microbiome trials you might be interested in

A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic LeukemiaPhase 1Recruiting

Relapsed Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaB-cell Acute Lymphoblastic LeukemiaPediatric CancerPediatric ALL, RelapsedPediatric ALLPediatric ALL, B CellAcute Myeloid LeukemiaAcute Lymphoblastic LeukemiaPediatric AMLR/R AMLR/R B-cell ALL

The goal of this clinical trial is to learn if sonrotoclax (BGB-11417) is safe and may help treat children and adolescen…

Multiple LocationsEst. completion Apr 30, 2030

View Trial →

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.